<DOC>
	<DOCNO>NCT00264420</DOCNO>
	<brief_summary>Zoledronic acid ( Zometa ) belong class drug call bisphosphonates . Bisphosphonates use bone metastasis keep cancerous lesion control bone help prevent calcium level elevation blood . Cancer cell-culture study Cleveland Clinic show zoledronic acid radiation together cell kill effect either one use alone . The purpose study monitor heal bone lesion use zoledronic acid together radiation treatment .</brief_summary>
	<brief_title>Safety Efficacy Study Concomitant Radiotherapy Zoledronic Acid Bone Metastases Palliation</brief_title>
	<detailed_description>Bone metastases frequently one first sign disseminate disease cancer patient . Skeletal complication due metastatic disease include ( severe ) bone pain , impaired mobility , spinal cord compression , pathological fracture , hypercalcemia . Radiotherapy surgery option specific local treatment bone metastasis . Chemotherapy , hormonotherapy bisphosphonates systemic weapon use treatment bone metastases without hypercalcemia . Cancers propensity metastasize bone breast , prostate , lung myeloma may possess capacity interact osteoclast . Osteoclasts specialize bone cell , erode mineralize bone secrete acid lysosomal enzyme . In normal bone remodeling , osteoclastic bone resorption couple equilibrium osteoblastic bone formation . The lytic bone destruction associate malignant bone metastasis develop tumor cell synthesize release soluble factor stimulate osteoclast resorb bone . The malignant activation osteoclast result disruption normal bone remodel wherein equilibrium bone resorption bone formation shift toward increase bone resorption . This relative increase osteoclastic bone resorption result net loss bone . Zoledronic acid ( Zometa® , CGP42446 ) member class compound know bisphosphonates . Bisphosphonates effective inhibitor osteoclastic bone resorption . They therapeutic efficacy treatment hypercalcemia malignancy , lytic bone disease associate multiple myeloma , mixed lytic blastic bone metastasis associate breast cancer , prostate cancer lung cancer . In clinical setting , zoledronic acid potent bisphosphonate . Conventionally , external beam radiotherapy ( RT ) primary treatment method palliation bone metastasis . The aim RT bone metastases treatment eradicate malignant cell without damage surround normal cell . RT typically give lesion area , order spare much bone marrow possible . RT indicate solitary , lytic painful bone lesion multiple myeloma well bone metastasis solid tumor breast , prostate lung cancer prevent fracture risk relieve pain . The goal study evaluate safety efficacy concomitant standard RT standard zoledronic acid bone metastasis breast , prostate lung cancer patient . We choose zoledronic acid use study , effective FDA approve aminobisphosphonate .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>&gt; 18 year age biopsy proven breast , lung , and/or prostate cancer boney metastases indication radiation , either diagnose radiologically biopsy proven Karnofsky Performance Status &gt; 60 Life expectancy least 6 month Serum creatinine level ≤ 2.0 mg/dL calculate creatinine clearance &gt; 60 mL/min Leukocyte count ≥ 3500/mm3 Hemoglobulin &gt; 11 g/dl Platelets &gt; 100,000 / mm3 Total bilirubin &lt; 2.5 mg/dl pregnant lactate woman ( breast lung cancer ) hormonotherapy start less 3 month prior randomization ( prostate cancer ) history allergic reaction bisphosphonates receive concomitant nephrotoxic chemotherapy participation another clinical trial investigational drug complete investigational drug trial within past 30 day liver function test &gt; 1.5 time normal value IV calcitonin administration le 30 day prior randomization laboratory evidence renal disease previous RT region bone metastasis treat study currently receive oral IV bisphosphonate therapy presence ascites clinically significant electrocardiographic change hypercalcemia , pathologic fracture , epidural spinal cord compression organ metastasis know hypersensitivity Zometa® ( zoledronic acid ) bisphosphonates current active dental problem include infection teeth jawbone ( maxilla mandibular ) ; dental fixture trauma , current prior diagnosis osteonecrosis jaw ( ONJ ) , expose bone mouth , slow healing dental procedure . recent ( within 6 week ) plan dental jaw surgery ( e.g.. extraction , implant )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>bone metastasis</keyword>
	<keyword>breast cancer</keyword>
	<keyword>lung cancer</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>radiation therapy</keyword>
</DOC>